SynthesisWorld journal of gastroenterology2011
P16 gene hypermethylation and hepatocellular carcinoma: a systematic review and meta-analysis.
Synthesis in World journal of gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 54 citations in OpenAlex.
- Pooled it
- BRAF inhibition increases TGFβ2 production and stimulates metastasis in mice with endogenous BRAFProceedings of the National Academy of Sciences of the United States of America · 2025Article
- Mallory-Denk bodies and hepatocellular senescence: a causal relationship?Virchows Archiv : an international journal of pathology · 2024Article
- Pathogenesis and Current Treatment Strategies of Hepatocellular Carcinoma.Biomedicines · 2022Review
- Cell-free methylation of RASSF1 and CDKN2AIP genes in the diagnosis of hepatocellular carcinoma associated with hepatitis B virus cirrhosis.Hepatology forum · 2022Article
- P16INK4A-More Than a Senescence Marker.Life (Basel, Switzerland) · 2022Review
- A novel defined cuproptosis-related gene signature for predicting the prognosis of colon adenocarcinoma.Frontiers in oncology · 2022Article
- Systematic Analysis of Cytostatic TGF-Beta Response in Mesenchymal-Like Hepatocellular Carcinoma Cell Lines.Journal of gastrointestinal cancer · 2021Article
- Progress of Signaling Pathways, Stress Pathways and Epigenetics in the Pathogenesis of Skeletal Fluorosis.International journal of molecular sciences · 2021Review
- Sex and Race-Related DNA Methylation Changes in Hepatocellular Carcinoma.International journal of molecular sciences · 2021Review
- Hypomethylation ofJournal of biosciences · 2021Article
- Epigenetic Mechanisms Involved in HCV-Induced Hepatocellular Carcinoma (HCC).Frontiers in oncology · 2021Review
- Loss of ARF/INK4A Promotes Liver Progenitor Cell Transformation Toward Tumorigenicity Supporting Their Role in Hepatocarcinogenesis.Gene expression · 2020Article
- Usefulness of Circulating Methylated p16 as a Noninvasive Molecular Biomarker for Hepatitis C-Related Hepatocellular Carcinoma with Normal Serum Alpha-Fetoprotein Levels.International journal of general medicine · 2020Article
- Five-CpG-based prognostic signature for predicting survival in hepatocellular carcinoma patients.Cancer biology & medicine · 2018Article
- The innovative regularity and role of p16 methylation in blood during HCC development.Journal of Cancer · 2018Article
- Accuracy of novel diagnostic biomarkers for hepatocellular carcinoma: An update for clinicians (Review).Oncology reports · 2016Review
- The Correlation Relationship between P14ARF Gene DNA Methylation and Primary Liver Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2015Article
- Molecular mechanisms of gender disparity in hepatitis B virus-associated hepatocellular carcinoma.World journal of gastroenterology · 2014Review
- Hepatitis B virus infection in patients with blood disorders: a concise review in pediatric study.Iranian journal of pediatric hematology and oncology · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimTo quantitatively investigate the effect of p16 hypermethylation on hepatocellular carcinoma (HCC) and hepatocirrhosis using a meta-analysis of available case-control studies.
methodsPrevious studies have primarily evaluated the incidence of p16 hypermethylation in HCC and corresponding control groups, and compared the incidence of p16 hypermethylation in tumor tissues, pericancer liver tissues, normal liver tissues and non-tumor liver tissues with that in other diseases. Data regarding publication information, study characteristics, and incidence of p16 hypermethylation in both groups were collected from these studies and summarized.
resultsFifteen studies, including 744 cases of HCC and 645 non-tumor cases, were identified for meta-analysis. Statistically significant odds ratios (ORs) of p16 hypermethylation were obtained from tumor tissues and non-tumorous liver tissues of HCC patients (OR 7.04, 95% CI: 3.87%-12.78%, P < 0.0001), tumor tissues of HCC patients and healthy liver tissues of patients with other diseases (OR 12.17, 95% CI: 6.64%-22.31%, P < 0.0001), tumor tissues of HCC patients and liver tissues of patients with non-tumorous liver diseases (OR 6.82, 95% CI: 4.31%-10.79%, P < 0.0001), and cirrhotic liver tissues and non-cirrhotic liver tissues (OR 4.96, 95% CI: 1.45%-16.96%, P = 0.01). The pooled analysis showed significantly increased ORs of p16 hypermethylation (OR 6.98, 95% CI: 4.64%-10.49%, P < 0.001) from HCC tissues and cirrhotic tissues.
conclusionP16 hypermethylation induces the inactivation of p16 gene, plays an important role in hepatocarcinogenesis, and is associated with an increased risk of HCC and liver cirrhosis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.